Tang Capital Management’s Fate Therapeutics FATE Stock Holding History

Tang Capital Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.4M	Hold	1,167,773	–	–	0.07%	48
2025 Q4	$1.15M	Sell	1,167,773 -700,000	-37%	-$841K	0.06%	70
2025 Q3	$2.35M	Hold	1,867,773	–	–	0.09%	121
2025 Q2	$2.09M	Hold	1,867,773	–	–	0.11%	115
2025 Q1	$1.48M	Buy	1,867,773 +11,819	+0.6%	+$14.5K	0.08%	136
2024 Q4	$3.06M	Buy	1,855,954 +1,155,954	+165%	+$2.91M	0.2%	91
2024 Q3	$2.45M	Hold	700,000	–	–	0.18%	92
2024 Q2	$2.3M	Hold	700,000	–	–	0.23%	75
2024 Q1	$5.14M	Hold	700,000	–	–	0.54%	57
2023 Q4	$2.62M	Hold	700,000	–	–	0.24%	83
2023 Q3	$1.48M	Hold	700,000	–	–	0.21%	85
2023 Q2	$3.33M	Hold	700,000	–	–	0.49%	56
2023 Q1	$3.99M	Buy	+700,000	New	+$4.22M	0.59%	46

Other funds holding FATE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tang Capital Management's FATE Position: Q1 2026 in Review

Tang Capital Management held its Fate Therapeutics (FATE) position steady in Q1 2026 at 1,167,773 shares worth $1.4M. The position accounts for 0.07% of the portfolio, ranked #48.

Tang Capital Management first reported a position in FATE in Q1 2023 and has held it in 13 quarters since. The position peaked at $5.14M in Q1 2024. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

Tang Capital Management held 1,167,773 shares of Fate Therapeutics worth $1.4M as of Q1 2026.
Tang Capital Management left its Fate Therapeutics share count unchanged in Q1 2026.
Fate Therapeutics made up 0.07% of Tang Capital Management's portfolio in Q1 2026, its #48 holding.
Tang Capital Management first reported a position in Fate Therapeutics in Q1 2023 and has held it in 13 quarters since.
Tang Capital Management's Fate Therapeutics position peaked at $5.14M in Q1 2024.
157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Tang Capital Management's 13F filing for Q1 2026, filed 15 May 2026.